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with humans are based on patients in the indeterminate and/or chronic
phase of Chagas disease, not answering the question of when those
AAbs were produced and what is their fate during the infection with
T. cruzi.
Sixty mongrel (all 4 months old) dogs were inoculated with three
different strains of T. cruzi (VL10, AAS and Y) by intraperitoneal route
with 4.0 × 103 bloodstream trypomastigotes per kg of body weight.
The infected animals with each of the strains were divided into two ex-
perimental groups: (i) 10 dogs were treated with Bz at 7.0 mg/kg twice
daily for 60 days after infection conﬁrmation by parasite detection; and
(ii) 10 dogs were maintained as non-treated controls [5]. Additional 10Chronic chagasic cardiomyopathy (CCC) is a public health problem
still without a deﬁned physiopathology. It results from a chronic infec-
tion by Trypanosoma cruzi and is characterized by irreversible lesions
to the heart. The contribution of autoimmune processes to cardiac dys-
functions observed in CCC has been hypothesized by several authors
[1–3]. Those studies demonstrated the presence of IgG components in
sera of patients with CCC and dilated cardiomyopathy interacting with
cardiac β1-adrenergic (anti-β1-AR) and muscarinic membrane recep-
tors (anti-M2-CR) [3]. Of note, sustained activation of β-adrenergic
receptors, particularly of the β1-subtype, promotes contractile dysfunc-
tion, ventricular arrhythmias and congestive heart failure with cardio-
myocyte hypertrophy and interstitial ﬁbrosis [3].
In the present work we investigated the existence and time-
dependent appearance of anti-β1-AR and anti-M2-CR AAbs in sera
from dogs infected by three different T. cruzi strains (VL10, AAS and Y)
and further, under modulation by benznidazole (Bz) (Roche, Rio de
Janeiro, Brazil) treatment. To our knowledge, this is the ﬁrst time that
a deﬁned time-course for antibody appearance is investigated in the ca-
ninemodel, which has a greater translational potential when comparedability and freedom from bias of
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animals were maintained as a non-infected and untreated control
group. Anti-β1-AR and anti-M2-CR AAbs were evaluated at 30 (acute
phase), 90 (early chronic phase) and 270 (late chronic phase) days
post-infection in sera samples by enzyme-linked immunosorbent
assay (ELISA). For AAbdetection by ELISA synthetic peptides comprising
the second extracellular loops of the β1 or M2 cardiac receptors were
used [6]. All animals were submitted to electrocardiographic (ECG)
exams before infection and at 9 months post-infection. All procedures
were conducted in accordance with the guidelines issued by the
Brazilian College of Animal Experimentation (COBEA) and approved
by the Ethics Committee in Animal Research at UFOP (protocol 98
number 2008/08).
Concerning the anti-β1-AR AAb titers, a similar pattern during the
course of infection with the different parasite strains was observed.
They appeared in all infected dogs at 30 dpi and were reduced at
90 dpi, recovering the acute phase levels at the late chronic phase
(Table 1). With respect to anti-M2-CR, they also appeared during the
acute phase of the disease however, the levels during progression of
the infection were highly variable, depending on parasite strain. Once
increased, the anti-M2-CR AAb levels for VL10 strain were maintained
elevated during the whole course of infection (Table 1). On the other
hand, the anti-M2-CR AAb levels for AAS strain had a clear peak at
30 dpi reducing at 90 days, and remained at similar levels at 270 dpi
(Table 1). Curiously, for the Y strain the anti-M2-CR AAb levels were
lower when compared to the other T. cruzi strains, especially at
30 dpi, and only 44% of the dogs were positive for this AAb (Table 1).
At 90 dpi the AAb titers were similar to 30 dpi, however increased sig-
niﬁcantly in the chronic phase (Table 1). The fact that both AAbs ap-
peared in the sera at an early stage of the infection with all the strains
Table 1
Autoantibody titers assessed by ELISA in dogs infected with three different strains of
Trypanosoma cruzi and their modulation by benznidazole treatment.
T. cruzi
strain
R (% of positivity)
30 dpi
Acute phase
90 dpi
Early chronic phase
270 dpi
Late chronic phase
Anti-β1-AR VL10 2.3 ± 0.2a (100) 1.0 ± 0.2b (0) 2.7 ± 0.9a,c (100)
AAS 3.0 ± 0.9a (100) 0.9 ± 0.2b (14) 1.9 ± 1.2a,d,e (75)
Y 2.3 ± 0.7a,§ (100) 0.7 ± 0.2b (22) 2.0 ± 0.8a,c,§§ (89)
Anti-M2-CR VL10 1.7 ± 0.6a (100) 1.6 ± 0.6a (33) 2.3 ± 0.6a (100)
AAS 3.1 ± 0.4a,§ (100) 1.4 ± 0.9a,b (50) 1.8 ± 1.1a,b (78)
Y 1.2 ± 0.3f (44) 0.8 ± 0.3g (33) 1.7 ± 0.7a,c,h (78)
ELISA values were expressed as the ratio (R) between the optical densities (OD)
determined for each sample and cut-off values. Cut-off was the mean OD of non-
infected animals plus 2 standard deviations (SD). Data are expressed as mean ± SD.
Positivity was deﬁned as R N 1.2.
a P b 0.001 versus non-infected control group.
b P b 0.001 versus 30 dpi.
c P b 0.001 versus 90 dpi.
d P b 0.01 versus 30 dpi.
e P b 0.01 versus 90 dpi.
f P b 0.01 versus non-infected control group.
g P b 0.05 versus non-infected control group.
h P b 0.05 versus 30 dpi.
§ Bz modulation P b 0.001.
§§ Bz modulation P b 0.05.
Table 2
Electrocardiographic ﬁndings at 270 days post-infection (dpi) of Trypanosoma cruzi-
infected dogs with VL10, AAS and Y strains treated (T) or not treated (NT) with
benznidazole.
VL10 NT VL10 T AAS NT AAS T Y NT Y T
Chamber overload 3/5 3/4 1/5 1/5 3/4 None
First degree atrioventricular
block
1/5 2/4 1/5 None None None
Other arrhythmiasa None None 3/5 None 2/4 None
Percentage of dogs with ECG
alterations
80 100 100 20 100 0
a Other arrhythmias include: supraventricular extrasystole,ﬁrst degree sinoatrial block,
bradycardia–tachycardia syndrome, atrial arrhythmia, incomplete right bundle branch
block, anterosuperior divisional block of the left bundle branch, complete right bundle
branch block, and premature ventricular contractions.
e67A. Daliry et al. / International Journal of Cardiology 170 (2014) e66–e67studied and that there was a strain-speciﬁc modulation of anti-M2-AAb
titers reinforces the hypothesis that those AAbs are produced as a re-
sponse to the parasite rather than a consequence of heart injury [7,8].
This hypothesis proposes that AAbs are produced against the parasites
and are able to cross-react with selective host antigens leading to auto-
immunity [7,8]. Similar to what was found by Wallukat [3] in chronic
chagasic patients, the majority of the infected animals are positive for
both anti-β1-AR and anti-M2-CR AAbs in the late chronic phase (75 to
100%, depending on the strain) (Table 1).
Bz treatment in dogs infected with VL10 strain did not change the
anti-β1-AR and anti-M2-CR AAb titers at all time-points evaluated, and
showed no improvement in ECG alterations (Table 1 and 2). On the
other hand, in dogs infected with AAS strain, Bz although not altering
anti-β1-AR AAb titers caused a 48% reduction in anti-M2-CR AAb titers
at 30 dpi (Table 1) and an 80% reduction in ECG abnormalities
(Table 2). Bz treatment in dogs infected with Y strain led to nomodula-
tion of anti-M2-CR AAb titers, a 35 and 30% reduction in anti-β1-AR AAb
titers at 30 and 270 dpi, respectively (Table 1) and 100% reduction of
ECG alterations (Table 2). Altogether, the absence of alterations in AAb
titers by Bz treatment was accompanied by a corresponding absence
of ECG modulation, while decreases in at least one of the AAb levels,
anti-β1-ARor anti-M2-CR,were always associated to ECG improvement.
We previously reported that Bz treatment reduced ﬁbrosis in dogs in-
fected with AAS and Y strains, while this drug did not alter collagen de-
position in dogs infected with VL10 strain [9]. Since increased ﬁbrosis is
a trigger for the development of arrhythmias, ourﬁndings are consistent
with the effects of Bz treatment in collagen deposition previously re-
ported. Recently, Cutrullis et al. [10] reported a signiﬁcant reduction of
serumanti-M2-CR titers in children in the indeterminate form of Chagasdisease when submitted to Bz treatment, however they could not asso-
ciate this ﬁnding with heart dysfunction as the patients did not show
any ECG or ECHO alterations.
Although IgGs with anti-β1-AR or anti-M2-CR reactivity are some-
times associated with cardiac function worsening in CCC, others have
not found such association. Our study indicates that AAb levels are in-
creased early throughout the course of infection suggesting that they
are produced in response to parasite presence. Additionally, the modu-
lation of AAb levels by Bz treatment is dependent on T. cruzi strain and
associated to ECG abnormality modulation.References
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